SCHEMBL4169795

SCHEMBL4169795

CCC(O)(CC)CCC=C(C)c1cccc(NCCc2ccc(C(O)O)cc2)c1

nearest known ligand 0.34

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.34
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
LMNA P02545 1/20 0.31
PPARA Q07869 1/20 0.31
CNR2 P34972 1/20 0.30
ADRB1 P08588 1/20 0.30
ADRB3 P13945 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4169798 0.83 VDR (0.40) KMT2AMEN1MAPT
SCHEMBL4169791 0.83 VDR (0.40) KMT2AMEN1MAPT
SCHEMBL6155411 0.78 LTB4R (0.39)
SCHEMBL2783957 0.78 MAOB (0.42)
SCHEMBL2781564 0.77 PPARA (0.35) KMT2APPARA
SCHEMBL6884477 0.76 KMT2A (0.55) KMT2AMEN1MAPTLMNA
SCHEMBL6155800 0.76 MRGPRX4 (0.45) LMNA
SCHEMBL6155508 0.74 VDR (0.39)
SCHEMBL6155432 0.72 MAOB (0.43)
SCHEMBL6155281 0.71 MAOB (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090004232-A1 BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-01 US claimed
EP-1686972-B1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES GALDERMA RES & DEV (FR) 2008-03-12 EP claimed
US-20070041910-A1 Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2007-02-22 US claimed
EP-1686972-A1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES Galderma Research & Development, S.N.C. (FR) 2006-08-09 EP claimed
WO-2005053666-A1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 WO claimed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP claimed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US claimed
US-20090004232-A1 BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-01 US disclosed
EP-1952808-A2 Composition in the form of a spray comprising calcitriol GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-08-06 EP disclosed
EP-1686972-B1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES GALDERMA RES & DEV (FR) 2008-03-12 EP disclosed
US-20070135379-A1 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-06-14 US disclosed
US-20070041910-A1 Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2007-02-22 US disclosed
EP-1686972-A1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES Galderma Research & Development, S.N.C. (FR) 2006-08-09 EP disclosed
WO-2005053666-A1 SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 WO disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135379-A1 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle IDUA, ARSA, STS KMT2A 1324/4885MEN1 351/4885MAPT 1004/4885
US-20070041910-A1 Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase CYP24A1, CYP2R1, VDR KMT2A 4836/4885MEN1 998/4885MAPT 1412/4885
US-20090004232-A1 BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF CYP19A1, CYP17A1, CYP51A1 KMT2A 2876/4885MEN1 1148/4885MAPT 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.